58175-07-8

Basic information

• Product Name: 1,4-dimethylquinoxaline-2,3(1H,4H)-dione
• Synonyms: 1,4-dimethylquinoxaline-2,3(1H,4H)-dione;1,4-Dimethyl-1,4-dihydro-quinoxaline-2,3-dione
• CAS NO: 58175-07-8
• Molecular Formula: C₁₀H₁₀N₂O₂
• Molecular Weight: 190.1986
• Mol File: 58175-07-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 316.4 °C at 760 mmHg
• Flash Point: 142.7 °C
• Appearance: /
• Density: 1.256 g/cm³
• Vapor Pressure: 0.000411mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: 1,4-dimethylquinoxaline-2,3(1H,4H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dimethylquinoxaline-2,3(1H,4H)-dione(58175-07-8)
• EPA Substance Registry System: 1,4-dimethylquinoxaline-2,3(1H,4H)-dione(58175-07-8)

Safety Data

• Hazardous Substances Data: 58175-07-8(Hazardous Substances Data)

Usage

General Description

1,4-dimethylquinoxaline-2,3(1H,4H)-dione, also known as DMQD, is a chemical compound with the molecular formula C10H10N2O2. It is a heterocyclic compound, containing two nitrogen atoms in a six-membered ring structure fused to a benzene ring. DMQD is used in the synthesis of pharmaceutical compounds and has been of interest for its potential biological activity. It has been studied for its antioxidant and antitumor properties, as well as its potential as a treatment for neurodegenerative diseases such as Alzheimer's and Parkinson's. Additionally, it has been investigated for its potential as a photoactivatable compound for use in photodynamic therapy. Despite its potential therapeutic applications, further research is needed to fully understand the pharmacological properties and potential uses of 1,4-dimethylquinoxaline-2,3(1H,4H)-dione.

InChI:InChI=1/C10H10N2O2/c1-11-7-5-3-4-6-8(7)12(2)10(14)9(11)13/h3-6H,1-2H3

Upstream product

• 15804-19-0 quinoxaline-2,3-dione 
• 20934-51-4 N-Methyl-1,4-dihydro-2,3-quinoxalinedione 
• 95-92-1 oxalic acid diethyl ester 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 
• 1204-75-7 3,4-Dihydro-3-oxo-2-quinoxalinecarboxylic acid 
• 612-28-2 2-nitro-N-methylaniline 
• 95-54-5 1,2-diamino-benzene 
• 4760-34-3 N-methyl-1,2-phenylenediamine 
• 74-88-4 methyl iodide 

Downstream Products

• 841275-84-1 1,4-dimethyl-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonyl chloride 

Relevant articles and documents

New quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: Design, synthesis, computational and bio-distribution studies

The current work represents the design and synthetic approaches of a new set of compounds 6-10 bearing the 1,4-dimethyl-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonamide scaffold. The biological evaluation revealed that most of the new compounds were promising selective dipeptidyl peptidase-IV (DPP-4) inhibitors and in vivo hypoglycemic agents utilizing linagliptin as a standard drug. The acute toxicity examination confirmed the safety profile of all compounds. Molecular docking studies related the significant DPP-4 suppression activity of compounds 9a, 10a, 10f, 10g to their nice fitting in the active pocket of DPP-4. In addition, the molecular dynamic study exhibited the stability of both 10a and 10g within the active site of DPP-4. The QSAR study showed that the difference between the predicted activities is very close to the experimental suppression effect. Moreover, both compounds 10a and 10g obeyed Lipinski's rule, indicating their efficient oral bioavailability. Compound 10a was radiolabeled, forming the 131I-SQ compound 10a to study the pharmacokinetic profile of this set of compounds. The biodistribution pattern hit the target protein since the tracer accumulated mainly in the visceral organs where DPP-4 is secreted in a high-level, thus with consequent stimulation of insulin secretion, leading to the target hypoglycemic effect.

Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof

The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals.